基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 抑制剂 JAK3-IN-6 化合物 JAK3-IN-6
  • 化合物 JAK3-IN-6|T5492|TargetMol

化合物 JAK3-IN-6|T5492|TargetMol

JAK3-IN-6
1443235-95-7
262 1mg 起订
369 2mg 起订
578 5mg 起订
上海 更新日期:2024-12-12

TargetMol中国(陶术生物)

VIP3年
联系人:邵小姐
手机:4008200310 拨打
邮箱:marketing@tsbiochem.com

产品详情:

中文名称:
化合物 JAK3-IN-6
英文名称:
JAK3-IN-6
CAS号:
1443235-95-7
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格:
99.94%
产品类别:
抑制剂
货号:
T5492

Product Introduction

Bioactivity

名称JAK3-IN-6
描述JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM
动物实验Female Lewis rats were purchased and housed . 48 rats were divided into six groups (n=8/group). Group 1 were drug-na?ve i.e. no compounds were administered throughout the study. On the afternoon of Day 1 (4pm), ABT or vehicle (1 ml/kg p.o.) was administered to Groups 2-5. Days 2-11 (8 am), each animal in Groups 2-5 were administered ABT 10 mpk qd (1 ml/kg p.o.), immediately followed by either vehicle or compound at 5ml/kg p.o. Group 6 animals received vehicle only (5 ml/kg p.o.). Days 2-11 (4 pm) Groups 2-5 were administered vehicle or compound at 5 ml/kg p.o. Animals were monitored and weighed throughout the study. On Day 10, under isoflurane anesthesia, 3 animals from Groups 2-6 were bled via the jugular vein for PK analysis at 4 and 8 h post-8 am dose. On Day 11, blood samples were collected, as described above, at 0 (16 h post-Day 10 pm dose) and 2 h post-am dose for PK, hematology, and clinical chemistry analysis. All remaining animals were euthanized at 2 hrs post-dosing on Day 11 and blood samples were collected for PK, hematology, and clinical chemistry analysis. Data were analyzed using Graphpad prism software. Statistical analyses were performed using a one-way ANOVA with Dunnett s post-hoc test for group comparisons to ABT + vehicle treatment.
体外活性一种强效的JAK3抑制剂(0.15 nM)在酶类实验中对JAK3的选择性是对JAK1的4300倍,而在细胞报告实验中对IL-2相比IL-6的选择性是67倍,对IL-2相比EPO或GMCSF的选择性是140倍,在人类PBMC实验中对IL-7相比IL-6或GMCSF的选择性是大于35倍。在体内,选择性抑制JAK3足以阻断炎症在类风湿关节炎大鼠模型中的发展,并且不影响造血。
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度DMSO : 40 mg/mL (114.17 mM), Sonication is recommended.
关键字inhibit | JAK3 IN 6 | JAK | Inhibitor | JAK3IN6 | JAK3-IN-6 | JAK-3-IN-6 | Janus kinase
相关产品JAK-IN-10 | Tofacitinib Citrate | Deucravacitinib | RO8191 | Ruxolitinib | KW-2449 | TAK-901 | CEP-33779 | Baricitinib | Fedratinib | Ruxolitinib phosphate | Delgocitinib
相关库抑制剂库 | 血管生成库 | 经典已知活性库 | 已知活性化合物库 | 激酶抑制剂库 | 高选择性抑制剂库 | 抗衰老化合物库 | NO PAINS 化合物库 | 表观遗传库 | 表型筛选靶点鉴定库
JAK3-IN-6|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 JAK3-IN-6相关厂家报价

内容声明
拨打电话 立即询价